Diabetes, Vol 44, Issue 6 665-671, Copyright © 1995 by American Diabetes Association

ARTICLES

Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension

M Giordano, M Matsuda, L Sanders, ML Canessa and RA DeFronzo
Department of Medicine, University of Texas Health Sciences Center, San Antonio 78284-7886, USA.

We compared the effects of captopril, nifedipine, and doxazosin on glucose and lipid metabolism in 30 hypertensive non-insulin-dependent diabetes mellitus (NIDDM) patients (age = 50 +/- 3 years; body mass index = 30 +/- 1 kg/m2). Of these patients, 9 were treated with captopril, 11 with nifedipine, and 10 with doxazosin for 12 weeks. Blood pressure, fasting plasma glucose (FPG) concentration, HbA1c, oral glucose tolerance test (OGTT), euglycemic insulin clamp, and plasma lipids were measured before and after a 3-month period. Mean arterial blood pressure (114 +/- 2 mmHg) was similar in all groups before initiating antihypertensive therapy and declined to 102 +/- 2 (captopril), 103 +/- 1 (nifedipine), and 103 +/- 2 (doxazosin) mmHg (P < 0.001). Baseline FPG (148 +/- 11 mg/dl) and HbA1c (6.3 +/- 1%) were similar in all groups and did not change significantly with treatment. Plasma glucose, insulin, and free fatty acid (FFA) concentrations during the OGTT were similar in all groups before antihypertensive treatment and did not change with captopril and nifedipine; after doxazosin, plasma glucose and FFA concentrations during the OGTT decreased (both P < 0.05) without change in plasma insulin response. Insulin-mediated glucose uptake (144 +/- 11 mg.m-2.min-1), glucose oxidation (76 +/- 4 mg.m-2.min-1), and nonoxidative glucose disposal (71 +/- 6 mg.m-2.min-1) were similar in all groups before the start of antihypertensive treatment and did not change in captopril and nifedipine groups.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Changes in Weight and Glucose Tolerance During Treatment With Mirtazapine Diabetes Care, January 1, 2006; 29(1): 170 - 171.

				G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. H. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, R. Oakes, M. A. Lukas, et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial JAMA, November 10, 2004; 292(18): 2227 - 2236. [Abstract] [Full Text] [PDF]

				G. Mancia, M. Brown, A. Castaigne, P. de Leeuw, C. R. Palmer, T. Rosenthal, G. Wagener, and L. M. Ruilope Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) Hypertension, March 1, 2003; 41(3): 431 - 436. [Abstract] [Full Text] [PDF]

				E. Bonora, G. Targher, M. Alberiche, R. C. Bonadonna, F. Saggiani, M. B. Zenere, S. Uleri, and M. Muggeo Effect of Chronic Treatment with Lacidipine or Lisinopril on Intracellular Partitioning of Glucose Metabolism in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1544 - 1550. [Abstract] [Full Text]

				G. N. Jyothirmayi, I. Alluru, and A. S. Reddi Doxazosin Prevents Proteinuria and Glomerular Loss of Heparan Sulfate in Diabetic Rats Hypertension, May 1, 1996; 27(5): 1108 - 1114. [Abstract] [Full Text]